Technical Analysis for ONC - Oncolytics Biotech Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.62% | |
| Outside Day | Range Expansion | 0.62% | |
| Gapped Up | Strength | 0.62% | |
| Overbought Stochastic | Strength | 0.62% | |
| Up 3 Days in a Row | Strength | 0.62% | |
| Up 4 Days in a Row | Strength | 0.62% | |
| Up 5 Days in a Row | Strength | 0.62% | |
| NR7 | Range Contraction | 1.24% | |
| NR7-2 | Range Contraction | 1.24% | |
| Narrow Range Bar | Range Contraction | 1.24% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 22 hours ago |
| Upper Bollinger Band Resistance | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Rose Above Upper Bollinger Band | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 2024-05-03
Oncolytics Biotech Inc. Description
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Clinic Cancer RTT Therapy Clinical Trial Oncology Lung Cancer Blastoma Chemotherapy Non Small Cell Lung Cancer Glioblastoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.49 |
| 52 Week Low | 1.2 |
| Average Volume | 71,457 |
| 200-Day Moving Average | 2.086 |
| 50-Day Moving Average | 1.461 |
| 20-Day Moving Average | 1.513 |
| 10-Day Moving Average | 1.542 |
| Average True Range | 0.063 |
| RSI (14) | 65.64 |
| ADX | 30.85 |
| +DI | 31.022 |
| -DI | 9.028 |
| Chandelier Exit (Long, 3 ATRs) | 1.450 |
| Chandelier Exit (Short, 3 ATRs) | 1.590 |
| Upper Bollinger Bands | 1.640 |
| Lower Bollinger Band | 1.385 |
| Percent B (%b) | 0.92 |
| BandWidth | 16.886 |
| MACD Line | 0.035 |
| MACD Signal Line | 0.021 |
| MACD Histogram | 0.0145 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.695 | ||||
| Resistance 3 (R3) | 1.693 | 1.667 | 1.683 | ||
| Resistance 2 (R2) | 1.667 | 1.648 | 1.668 | 1.678 | |
| Resistance 1 (R1) | 1.643 | 1.636 | 1.630 | 1.645 | 1.674 |
| Pivot Point | 1.617 | 1.617 | 1.610 | 1.618 | 1.617 |
| Support 1 (S1) | 1.593 | 1.598 | 1.580 | 1.595 | 1.566 |
| Support 2 (S2) | 1.567 | 1.586 | 1.568 | 1.562 | |
| Support 3 (S3) | 1.543 | 1.567 | 1.558 | ||
| Support 4 (S4) | 1.545 |
